



Investor Presentation

Curt R. Hartman
President, Chief Executive Officer and Chair of the Board

Todd Garner
Executive Vice President & Chief Financial Officer

October 28, 2020



Forward-Looking Information

This presentation contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this presentation involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this presentation include, but are not limited to, the risks posed to the Company's business, financial condition, and results of operations by the COVID-19 global pandemic and the various government responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2019, and listed under the heading Forward-Looking Statements in the Company's most recently filed Form 10-Q.

Management has disclosed adjusted financial measurements in this presentation that present financial information that is not in accordance with generally accepted accounting principles (GAAP). These adjusted financial measures are helpful to management in comparing the recurring aspects of the business performance without the effect of unusual, non-recurring or special revenues or costs. These measurements are not a substitute for GAAP measurements. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

CONMED Vision

Empower healthcare providers worldwide to deliver exceptional outcomes for patients.

Focus behind the Vision

People

Products

Enhancing profitability



WE OPERATE
with urgency.



WE MAKE
and keep
commitments.



WE DO
things the
right way.



WE DELIVER
exceptional results.



WE BELIEVE
in the power of
engaged talent.

Objectives for Our Shareholders

- Aggregate growth and profitability over the long term to significantly increase the valuation of the company
- Increase our market share in large and attractive markets
- Deliver above-market revenue and profitability growth over the long term

Q3 2020 Results


- Revenue: \$237.8M, an increase of 1.8% year over year as reported and in constant currency
- GAAP EPS: Diluted net earnings per share of \$0.23, compared to diluted net earnings per share of \$0.23 in the third quarter of 2019
- Adjusted EPS¹: Diluted net earnings per share of \$0.88, compared to diluted net earnings per share of \$0.62 in the third quarter of 2019

Third quarter results were meaningfully impacted by the global COVID-19 pandemic

¹Excludes the costs of special items, including, restructuring and related costs, acquisition and integration, manufacturing consolidation, amortization of intangible assets, deferred financing fees and debt discount, net of tax.

Orthopedics: Large, Attractive Markets

Full-Year 2019




71%

Recurring, single-use revenue

Category	Description	Market Size and Competitors	Dollar Value of 1 Market Share Point
Sports Medicine	Devices for repair of soft tissue injuries in joints	\$4.4 to \$4.6 Billion <ul style="list-style-type: none"> ▪ Arthrex ▪ DePuy Mitek (J&J) ▪ Smith & Nephew ▪ Stryker ▪ Zimmer Biomet 	~\$45M
Allograft Tissue	Exclusive commercial rights to MTF allograft tissue	\$375 to \$425 Million <ul style="list-style-type: none"> ▪ Allosource ▪ LifeNet ▪ RTI 	~\$4M
Powered Instruments	Surgical drills and saws with related single-use accessories	\$1.4 to \$1.6 Billion <ul style="list-style-type: none"> ▪ Stryker ▪ DePuy Synthes (J&J) ▪ Medtronic (Midas Rex / Xomed) ▪ Zimmer Biomet 	~\$15M
Surgical Visualization	High-definition surgical visualization systems to enable minimally invasive arthroscopic surgery	\$1.8 to \$2.0 Billion <ul style="list-style-type: none"> ▪ Stryker ▪ Arthrex ▪ Karl Storz ▪ Olympus ▪ Richard Wolf ▪ Smith & Nephew 	~\$19M
<u>Total Orthopedics</u>			~\$83M ~8% growth for total company

General Surgery: Large, Attractive Markets

Full-Year 2019



87%
Recurring, single-use revenue

Category	Description	Market Size and Competitors	Dollar Value of 1 Market Share Point
Access	A platform of devices and accessories to create and enter the surgical working space in minimally invasive procedures	\$1.4 to \$1.6 Billion <ul style="list-style-type: none"> ▪ Ethicon (J&J) ▪ Applied Medical ▪ Stryker ▪ Medtronic ▪ Olympus ▪ Karl Storz 	~\$15M
Energy	RF energy to affect tissue by cutting, sealing, or causing hemostasis in open or minimally invasive procedures. Smoke evacuation and filtration to support the surgical environment	\$2.6 to \$2.8 Billion <ul style="list-style-type: none"> ▪ Medtronic ▪ Ethicon (J&J) ▪ Olympus ▪ Stryker ▪ Cooper Surgical ▪ ERBE 	~\$27M
Instruments	Instruments and accessories for minimally invasive laparoscopic, open, and robotic approaches	\$1.5 to \$1.7 Billion <ul style="list-style-type: none"> ▪ Karl Storz ▪ Aesculap ▪ Stryker 	~\$16M
Endoscopic Technologies	Therapeutic and diagnostic endoscopic products used by Gastroenterologists	\$3.0 to \$3.2 Billion <ul style="list-style-type: none"> ▪ Boston Scientific ▪ Cook Medical ▪ Cantel ▪ Olympus ▪ Merit Endotek ▪ STERIS 	~\$31M
Critical Care	Single-use devices for monitoring cardiac activity and other patient care devices	\$0.8 to \$1.0 Billion <ul style="list-style-type: none"> ▪ 3M Company ▪ Cardinal 	~\$9M
<u>Total General Surgery</u>			~\$98M ~10% growth for total company

Closing Thoughts

- Intense focus on the healthcare customer and solving their unmet needs drives increased market share
- Large and attractive markets provide CONMED with ample opportunities for above-average revenue and profitability growth
- Aggregating that growth over the long term can drive meaningful shareholder value
- At CONMED, we are focused on doing things the right way and being good corporate citizens